3.0.0 2157 2023-01-11T13:39:21Z 2023-01-11T13:39:21Z Senate S 2017-11-16 115 sshr00 Health, Education, Labor, and Pensions Committee Senate Standing Referred to 2017-11-16T22:21:57Z Drug-Price Transparency in Communications Act 115 6576 HR 2018-07-27 Referred to the Subcommittee on Health. Identical bill CRS 2017-11-16 sshr00 Health, Education, Labor, and Pensions Committee Senate Read twice and referred to the Committee on Health, Education, Labor, and Pensions. IntroReferral 2017-11-16 Introduced in Senate IntroReferral 10000 9 Library of Congress D000563 Sen. Durbin, Richard J. [D-IL] Richard Durbin D IL J. N K000383 Sen. King, Angus S., Jr. [I-ME] Angus King I ME S. 2017-11-16 True B000944 Sen. Brown, Sherrod [D-OH] Sherrod Brown D OH 2017-11-16 True F000457 Sen. Franken, Al [D-MN] Al Franken D MN 2017-11-16 True H001076 Sen. Hassan, Margaret Wood [D-NH] Maggie Hassan D NH 2017-11-16 True H001075 Sen. Harris, Kamala D. [D-CA] Kamala Harris D CA D. 2017-11-16 True G000555 Sen. Gillibrand, Kirsten E. [D-NY] Kirsten Gillibrand D NY E. 2017-12-14 False B001277 Sen. Blumenthal, Richard [D-CT] Richard Blumenthal D CT 2018-06-20 False Health Health 00 2017-11-16 Introduced in Senate 2019-08-29T21:20:06Z Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.

]]> Drug-Price Transparency in Communications Act Display Title Drug-Price Transparency in Communications Act Short Titles as Introduced Drug-Price Transparency in Communications Act Official Title as Introduced A bill to require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug. Introduced in Senate 2017-11-16T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-115s2157is/xml/BILLS-115s2157is.xml 2017-11-16 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.